SR-aGvHD

• HSCT is a treatment in which HSCs of donors are administered to the recipient veins to treat intractable blood diseases.

​

• Transplanted HSCs are attached to recipient’s bone marrow and differentiate to platelets, red blood cells, and white blood cells.

​

• The acute systemic inflammatory disease in which the transplanted immune cells attack the patient's body is called aGvHD.

​

• About 40,000 patients undergo HSCT around the world (2021), of which about 25% patients developed deceased by SR-aGvHD that because conventional treatments including steroids with immunosuppressant are not effective.

• As a result of non-clinical testing using IntenCell®, the survival rate increased by more than 30%P compared to naïve MSC treatments.

​

• Currently, phase 1 clinical trials are being approved by the Ministry of Food and Drug Safety (South Korea) and ongoing clinical trials.

​

• If clinical trials are conducted, overall survivor rate of IntenCell®-treated patients were predicted at least 85% compared to existing naïve MSC treatments.